Loading stock data…
AZN
$184.92+3.68 (+2.03%)
Pre-Market$184.77-0.15 (-0.08%)· Last close May 6
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at $184.92. The stock is currently 13% below its 52-week high of $212.71, remaining 4.7% above its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why AZN maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$184.92
Potential Downside
28%
Whystock Fair Value$133.11
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$223.79+21.0%
Range$184.00 – $243.00
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$302.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.74
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
161.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.04%
Volume
Today's trading volume
1.95M
Recent News
SOPHiA GENETICS Q1 Earnings Call Highlights
SOPHiA GENETICS (NASDAQ:SOPH) reported first-quarter 2026 revenue of $21.7 million, up 22% from $17.8 million in the prior-year period, as demand increased for its SOPHiA DDM analytics platform and the company expanded its installed base of clinical customers and applications. Revenue growth and re
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
ABBV jumps 5% after a Q1 beat and higher 2026 guidance, but Skyrizi, Rinvoq and a deep pipeline may matter more for its post-earnings outlook
Factbox-Global drugmakers rush to boost US presence as tariff threat looms
May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut
Strong Results and Improved Guidance Lifted AstraZeneca PLC (AZN)
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and […]
Mixed FDA Votes On Truqap And Camizestrant Refocus AstraZeneca Oncology Risk
FDA advisory panel backs AstraZeneca’s Truqap as the first targeted therapy for PTEN deficient metastatic hormone sensitive prostate cancer. The same panel issues a negative vote on breast cancer drug camizestrant for first line use in HR positive/HER2 negative advanced disease with emergent ESR1 mutations. Both decisions are based on clinical data showing progression free survival and quality of life outcomes, but reach different regulatory conclusions. AstraZeneca (LSE:AZN), trading...